Immutep Limited

NasdaqGM:IMMP Rapport sur les actions

Capitalisation boursière : US$59.2m

Immutep Gestion

Gestion contrôle des critères 2/4

Le PDG Immutep est Marc Voigt, nommé en Nov2012, a un mandat de 13.5 ans. La rémunération annuelle totale est A$ 1.17M, composée du salaire de 46.5% et des bonus 53.5%, y compris les actions et options de la société. détient directement 1% des actions de la société, d'une valeur de $ 593.89K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 8.4 ans et 4 ans.

Informations clés

Marc Voigt

Directeur général

AU$1.2m

Rémunération totale

Pourcentage du salaire du PDG46.51%
Durée du mandat du directeur général13.5yrs
Propriété du PDG1.0%
Durée moyenne d'occupation des postes de direction8.4yrs
Durée moyenne du mandat des membres du conseil d'administration4yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • May 08

Immutep Limited: Surging On Positive Head And Neck Data

Summary Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues. Despite promising phase 2 data, the fate of eftilagimod remains uncertain, with future trials and FDA discussions critical for potential accelerated approval. The positive TACTI-003 readout strengthens my "Buy" sentiment, though risks remain in this challenging cancer treatment landscape. Read the full article on Seeking Alpha
Seeking Alpha • Jan 28

Immutep Limited: Continuing To Make The Case For Eftilagimod

Summary Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential. Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials without immediate funding concerns. Recent clinical data suggest meaningful advancements in LAG-3 therapeutics, reinforcing the investment thesis and highlighting IMMP's undervalued status. Read the full article on Seeking Alpha
Seeking Alpha • Nov 15

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Summary Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data from the phase 1 INSIGHT-003 study is expected in 2025, with plans to initiate a phase 3 TACTI-004 study targeting the same patient population. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031. Results from the phase 2b TACTI-003 study, using efti + KEYTRUDA to treat 1st-line recurrent/metastatic head and neck squamous cell carcinoma, expected in 2025; OS set as primary endpoint. Read the full article on Seeking Alpha
Seeking Alpha • Jul 15

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Summary Immutep Limited achieved positive results in the phase 2b study, using efti + Keytruda for the treatment of patients with 1st-line head and neck squamous cell carcinoma; Both PD-L1 positive and negative patients. Company to meet with FDA to be in a position to initiate a phase 3 study using efti + Keytruda for the treatment of patients with 1st-line HNSCC. Merck supply collaboration agreement in place to advance phase 3 study, using efti + Keytruda + chemotherapy for the treatment of 1stline NSCLC patients. Keytruda had become one of the top-selling drugs in 2023, with sales exceeding $25 billion; Efti has shown to help double several efficacy measures when added to Keytruda. Read the full article on Seeking Alpha
Seeking Alpha • May 01

Immutep: Realizing The Expected Catalysts, With More To Come

Summary Immutep Limited is focused on developing novel treatments targeting LAG3, an immune checkpoint, for various tumor types. The company's pipeline includes eftilagimod, which has shown promising response rates in thoracic malignancies. Immutep should have sufficient funding for 9–10 quarters of research and has demonstrated promising early signals of efficacy and safety. Read the full article on Seeking Alpha
Seeking Alpha • Oct 04

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

The U.S. Food and Drug Administration (FDA) granted fast track designation to Immutep's (NASDAQ:IMMP) eftilagimod alpha (IMP321) in combination with Merck's (NYSE:MRK) Keytruda (pembrolizumab) to treat first line non-small cell lung cancer (NSCLC). The combo was granted the status for initial treatment of patients with stage 3B/4 NSCLC expressing PD-L1 Tumor Proportion Score ≥1%, not amenable to EGFR/ALK based therapy, due to data from a phase 2 trial called TACTI-002/KEYNOTE-798, the company said in an Oct. 4 press release. "Efti also offers a chemotherapy-free option for NSCLC patients in need of less toxic and more durable solutions," said Immutep CEO Marc Voigt. The efti/Keytruda combo had previously received the FDA's fast track status in April 2021 as a first-line treatment for recurrent or metastatic Head and Neck Squamous Cell Carcinoma. IMMP +7.21% to $1.71 premarket Oct. 4
Seeking Alpha • Sep 23

Immutep secures €1.8M cash in French government's research tax credit

Immutep (NASDAQ:IMMP) announced Friday it has received €1.8M cash from the French government in research and development tax incentive payment. The incentive comes under the government's research tax credit scheme under which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure. The biotech firm said it intends to use the proceeds to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761. Stock is up 5% in pre-market trading. Earlier: Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo
Seeking Alpha • Aug 30

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Immutep (NASDAQ:IMMP) said the Japanese Patent Office granted a new patent for eftilagimod alpha in combination with a PD-1 pathway inhibitor. The patent titled, 'Combined Preparations for the Treatment of Cancer or Infection' protects intellectual property related to combined therapeutic preparations consisting of  immunotherapy candidate eftilagimod alpha and an anti-PD-(L)1 antibody, the company said in an Aug. 30 press release. The company added that the claims are also directed to related methods of use in treating cancer and infection. "This is especially meaningful when coupled with the very promising data we have reported from TACTI-002 in three cancer indications, along with the initiation of TACTI-003 in the past 12 months," said Immutep CEO Marc Voigt. The patent is expected to expire Jan. 8, 2036.
Seeking Alpha • Jul 06

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Immutep (NASDAQ:IMMP) said it received a patent from the Japanese Patent Office related to its pre-clinical product candidate IMP761. The patent number number 7074341 titled 'Anti-LAG-3 Antibodies' is related to pharmaceutical compositions comprising IMP761 and the use of the compositions to treat T-cell mediated inflammatory and autoimmune diseases, according to the company's July 6 press release. The patent will expiry on Sept. 1, 2036.
Seeking Alpha • Jun 12

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Immutep has been developing anti-LAG3 compounds for over a decade. Recent approval of the first such compound from BMY was a watershed event. However, IMMP has a long way to go.
Seeking Alpha • Mar 21

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

FDA approval of Bristol Myers Opdualag/relatlimab anti-LAG3 carries positive implications for LAG3 pure-play Immutep’s entire pipeline. From an anti-LAG3 perspective, the FDA approval is directly positive for Immutep's recently unveiled oral, small molecule anti-LAG3 program and its out-licensed anti-LAG3 program to Novartis. Like anti-PD1 (Keytruda, Opvido) & anti-CLTA4 (Yervoy), LAG3 may be a key checkpoint in oncology. Yet, unlike PD1/CTLA4, LAG3 is unique in that both its activation & inhibition kills cancer. This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc. As its clinical data continues to strengthen, like it consistently has over the past few years, Immutep is seemingly well situated for strategic deals or its potential acquisition.
Seeking Alpha • Jun 21

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Immutep (IMMP) has signed an agreement to commence a new Phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha (“efti” or “IMP321”) in conjunction with an existing approved standard of care therapy consisting of a chemotherapy agent and an anti-PD-1 therapy. INSIGHT-003 will be run as an amendment to the protocol of the ongoing INSIGHT trial as the third arm (Stratum C) with Prof. Dr. Salah-Eddin Al-Batran as lead investigator. Up to 20 patients

Analyse de la rémunération des PDG

Comment la rémunération de Marc Voigt a-t-elle évolué par rapport aux bénéfices de Immutep?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2025n/an/a

-AU$84m

Sep 30 2025n/an/a

-AU$73m

Jun 30 2025AU$1mAU$546k

-AU$61m

Mar 31 2025n/an/a

-AU$53m

Dec 31 2024n/an/a

-AU$44m

Sep 30 2024n/an/a

-AU$43m

Jun 30 2024AU$1mAU$477k

-AU$43m

Mar 31 2024n/an/a

-AU$42m

Dec 31 2023n/an/a

-AU$41m

Sep 30 2023n/an/a

-AU$40m

Jun 30 2023AU$1mAU$440k

-AU$40m

Mar 31 2023n/an/a

-AU$38m

Dec 31 2022n/an/a

-AU$37m

Sep 30 2022n/an/a

-AU$34m

Jun 30 2022AU$943kAU$428k

-AU$32m

Mar 31 2022n/an/a

-AU$29m

Dec 31 2021n/an/a

-AU$26m

Sep 30 2021n/an/a

-AU$28m

Jun 30 2021AU$995kAU$409k

-AU$30m

Mar 31 2021n/an/a

-AU$29m

Dec 31 2020n/an/a

-AU$27m

Sep 30 2020n/an/a

-AU$20m

Jun 30 2020AU$926kAU$411k

-AU$13m

Mar 31 2020n/an/a

-AU$15m

Dec 31 2019n/an/a

-AU$16m

Sep 30 2019n/an/a

-AU$17m

Jun 30 2019AU$837kAU$399k

-AU$18m

Rémunération vs marché: La rémunération totale de Marc ($USD 842.04K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 624.15K ).

Rémunération et revenus: La rémunération de Marc a augmenté alors que l'entreprise n'est pas rentable.

PDG

Marc Voigt (52 yo)

13.5yrs
Titularisation
AU$1,174,480
Compensation

Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Marc Voigt
CEO, MD13.5yrsAU$1.17m1%
$ 593.9k
Deanne Miller
COO, General Counsel & Joint Company Secretary13.6yrsAU$680.39k0.19%
$ 115.1k
Frederic Triebel
Chief Scientific Officer & Executive Director11.4yrsAU$945.88k0.78%
$ 462.7k
Christian Mueller
Chief Development Officer2.6yrsAU$505.98k0.26%
$ 151.5k
Stephan Winckels
Chief Medical Officerless than a yearpas de données0.0063%
$ 3.7k
Indira Naidu
Joint Company Secretary5.3yrspas de donnéespas de données
8.4yrs
Durée moyenne de l'emploi
52yo
Âge moyen

Gestion expérimentée: L'équipe dirigeante de IMMP est chevronnée et expérimentée (8.4 années d'ancienneté moyenne).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Marc Voigt
CEO, MD11.8yrsAU$1.17m1%
$ 593.9k
Frederic Triebel
Chief Scientific Officer & Executive Director3.7yrsAU$945.88k0.78%
$ 462.7k
Russell Howard
Independent Non-Executive Chairman13yrsAU$352.00k0.12%
$ 69.0k
Pete Meyers
Independent Non-Executive Deputy Chairman12.3yrsAU$76.48k0.27%
$ 162.7k
Martine Piccart
Chairman of Clinical Advisory Board8.9yrspas de donnéespas de données
Scott Antonia
Member of Clinical Advisory Board4yrspas de donnéespas de données
Leisha Emens
Member of Clinical Advisory Board4yrspas de donnéespas de données
Elisabeth Boyce
Independent Non-Executive Director3.1yrsAU$100.85k0.029%
$ 17.0k
Salah-Eddin Al-Batran
Member of Clinical Advisory Board8.9yrspas de donnéespas de données
Martin Forster
Member of Clinical Advisory Board4yrspas de donnéespas de données
Hans Wildiers
Member of Clinical Advisory Board4yrspas de donnéespas de données
4.0yrs
Durée moyenne de l'emploi
62.5yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de IMMP sont considérés comme expérimentés (ancienneté moyenne 4 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/26 03:22
Cours de l'action en fin de journée2026/05/26 00:00
Les revenus2025/12/31
Revenus annuels2025/06/30

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Immutep Limited est couverte par 14 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Melissa BensonBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Dylan DupuisB. Riley Securities, Inc.